Table 1.
Study Characteristics.
| Reference | Groups | Sample size | Median Age (years) | Race/ethnic group– white % | Race/ ethnic group– black or African American% | Race/ ethnic group– Asian % | Males (%) | Females (%) | DM2 (%) | HTN (%) | Obesity (%) | Corticosteroids (%) | Remdesivir (%) | Mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACTT-2 | Baricitinib + Remdesivir | 515 | 55.0±15.4 | 48.7 | 15 | 9.5 | 62 | 38 | 39 | 51 | 58 | N/A | 100 | 4.67% |
| Placebo + Remdesivir | 518 | 55.8±16.0 | 47.3 | 15.3 | 10 | 64 | 36 | 35 | 52 | 53 | N/A | 100 | 7.14% | |
| COV-BARRIER | Baricitinib | 764 | N/A | 64 | 5 | 11 | 64 | 36 | 29 | 48 | 33 | 80 | 18 | 8% |
| Placebo | 761 | N/A | 59 | 5 | 13 | 62 | 38 | 31 | 48 | 33 | 78 | 19 | 13% | |
| COV-BARRIER (severe) | Baricitinib + Usual care | 51 | 58.4 | 64 | 2 | 0 | 49 | 51 | 39 | 61 | 55 | 84 | 0 | 39.2% |
| Placebo + Usual care | 50 | 58.8 | 61 | 2 | 2 | 60 | 40 | 32 | 48 | 58 | 88 | 2 | 58% | |
| RECOVERY | Baricitinib | 4148 | 58.5 | 77 | 11 | 66 | 34 | 23 | N/A | N/A | 96 | 21 | 12% | |
| Usual care | 4008 | 57.7 | 77 | 11 | 66 | 34 | 23 | N/A | N/A | 95 | 20 | 14% | ||